Last reviewed · How we verify
Ethinyl Estradiol-cyprosterone acetate
Ethinyl Estradiol-cyprosterone acetate is a Oral contraceptive; combined estrogen-progestin Small molecule drug developed by S.C.B. Medical College and Hospital. It is currently FDA-approved for Contraception, Acne vulgaris associated with hyperandrogenism, Hirsutism.
Ethinyl estradiol-cyproterone acetate is an oral contraceptive that suppresses ovulation through combined estrogenic and progestagenic activity while providing anti-androgenic effects.
Ethinyl estradiol-cyproterone acetate is an oral contraceptive that suppresses ovulation through combined estrogenic and progestagenic activity while providing anti-androgenic effects. Used for Contraception, Acne vulgaris associated with hyperandrogenism, Hirsutism.
At a glance
| Generic name | Ethinyl Estradiol-cyprosterone acetate |
|---|---|
| Sponsor | S.C.B. Medical College and Hospital |
| Drug class | Oral contraceptive; combined estrogen-progestin |
| Target | Estrogen receptor; progesterone receptor; androgen receptor (antagonist) |
| Modality | Small molecule |
| Therapeutic area | Gynecology; Endocrinology |
| Phase | FDA-approved |
Mechanism of action
The ethinyl estradiol component acts as a synthetic estrogen that inhibits the luteinizing hormone (LH) surge necessary for ovulation. Cyproterone acetate functions as a progestin and androgen receptor antagonist, providing additional contraceptive efficacy through cervical mucus thickening and endometrial changes, while simultaneously blocking androgenic effects. This combination is particularly effective for conditions associated with hyperandrogenism.
Approved indications
- Contraception
- Acne vulgaris associated with hyperandrogenism
- Hirsutism
- Polycystic ovary syndrome (PCOS)-related symptoms
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ethinyl Estradiol-cyprosterone acetate CI brief — competitive landscape report
- Ethinyl Estradiol-cyprosterone acetate updates RSS · CI watch RSS
- S.C.B. Medical College and Hospital portfolio CI
Frequently asked questions about Ethinyl Estradiol-cyprosterone acetate
What is Ethinyl Estradiol-cyprosterone acetate?
How does Ethinyl Estradiol-cyprosterone acetate work?
What is Ethinyl Estradiol-cyprosterone acetate used for?
Who makes Ethinyl Estradiol-cyprosterone acetate?
What drug class is Ethinyl Estradiol-cyprosterone acetate in?
What development phase is Ethinyl Estradiol-cyprosterone acetate in?
What are the side effects of Ethinyl Estradiol-cyprosterone acetate?
What does Ethinyl Estradiol-cyprosterone acetate target?
Related
- Drug class: All Oral contraceptive; combined estrogen-progestin drugs
- Target: All drugs targeting Estrogen receptor; progesterone receptor; androgen receptor (antagonist)
- Manufacturer: S.C.B. Medical College and Hospital — full pipeline
- Therapeutic area: All drugs in Gynecology; Endocrinology
- Indication: Drugs for Contraception
- Indication: Drugs for Acne vulgaris associated with hyperandrogenism
- Indication: Drugs for Hirsutism
- Compare: Ethinyl Estradiol-cyprosterone acetate vs similar drugs
- Pricing: Ethinyl Estradiol-cyprosterone acetate cost, discount & access